- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Apellis Pharmaceuticals Inc (APLS)Apellis Pharmaceuticals Inc stock price live, this page displays NASDAQ APLS stock exchange data. View the APLS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Apellis Pharmaceuticals Inc real time stock price chart below.
What Is the Apellis Pharmaceuticals Inc Stock Price Today?
The Apellis Pharmaceuticals Inc stock price today is 33.49.
What Is the Stock Symbol for Apellis Pharmaceuticals Inc?
The stock symbol for Apellis Pharmaceuticals Inc is "APLS."
What Stock Exchange Does Apellis Pharmaceuticals Inc Trade On?
Apellis Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Apellis Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Apellis Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the APLS quote. (ISIN: US03753U1060)
What Is the Apellis Pharmaceuticals Inc Stock Price Today?
The Apellis Pharmaceuticals Inc stock price today is 33.49.
What Is the Stock Symbol for Apellis Pharmaceuticals Inc?
The stock symbol for Apellis Pharmaceuticals Inc is "APLS."
What Stock Exchange Does Apellis Pharmaceuticals Inc Trade On?
Apellis Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Apellis Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Apellis Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the APLS quote. (ISIN: US03753U1060)
33.49
+0.04(+0.12%)
Closed
After Hours
33.01-0.46(-1.37%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
33.16
34.37
52 wk Range
24.34
73.80
APLS Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
33.1634.37
52 wk Range
24.3473.80
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockAPLS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Price Target
45.75
Upside
+36.61%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings downwards for the upcoming period
- Morgan Stanley sets Apellis stock at Equalweight
- Investing.com
- Morgan Stanley sets Apellis stock at Equalweight
- Investing.com
- Apellis Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Apellis Pharmaceuticals Inc Company Profile
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Compare APLS to Peers and Sector
Metrics to compare | APLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAPLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −16.7x | −1.1x | −0.7x | |
PEG Ratio | −0.27 | −0.01 | 0.00 | |
Price/Book | 17.6x | 0.7x | 2.6x | |
Price / LTM Sales | 5.8x | 7.9x | 3.2x | |
Upside (Analyst Target) | 37.4% | 259.0% | 46.6% | |
Fair Value Upside | Unlock | 8.5% | 7.4% | Unlock |
Analysts' Recommendations
15 Buy
7 Hold
0 Sell
Ratings:
20 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 45.75
(+36.61% Upside)
People Also Watch
FAQ
What Is the Apellis Pharma (APLS) Stock Price Today?
The Apellis Pharma stock price today is 33.49
What Stock Exchange Does Apellis Pharma Trade On?
Apellis Pharma is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Apellis Pharma?
The stock symbol for Apellis Pharma is "APLS."
What Is the Apellis Pharma Market Cap?
As of today, Apellis Pharma market cap is 4.17B.
What is Apellis Pharma Earnings Per Share?
The Apellis Pharma EPS is -2.03.
What Is the Next Apellis Pharma Earnings Date?
Apellis Pharma will release its next earnings report on 03 Mar 2025.
From a Technical Analysis Perspective, Is APLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.